The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1308
Focalin XR for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing. Long-acting MPH preparations with once-daily dosing have therefore become the mainstay of clinical practice.1 Recently the FDA approved a labeling change that apparently permits Novartis to say that one of these long-acting formulations, dexmethylphenidate extended-release capsules (d-MPH ER; Focalin XR), “starts working by 30 minutes”. Dexmethylphenidate is the active enantiomer of racemic MPH.2

LONG-ACTING METHYLPHENIDATE FORMULATIONS — Single-Pulse (Ritalin-SR, Metadate ER, Methylin ER) – Single-pulse, sustained-release MPH formulations use a wax matrix to prolong release. They have a duration of action of up to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Focalin XR for ADHD
Article code: 1308b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian